IMUX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immunic Inc (IMUX) is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 to invest. The stock has encouraging clinical and analyst support, but the current setup is still too speculative: there is no clear bullish technical breakout, no Intellectia buy signal, and the latest financials remain deeply loss-making. My direct view is to hold off on buying today and wait for stronger confirmation.
IMUX is trading pre-market at 9.90, up 2.91%, with the current quoted price near 9.62. Technically, momentum is mixed to slightly weak: MACD histogram is -0.0741 and still below zero, though it is negatively contracting, which suggests bearish pressure is easing. RSI_6 at 43.419 is neutral and does not indicate an oversold bounce or strong strength. Moving averages are converging, which usually signals a potential turning point, but not yet a confirmed trend. Price is sitting around the pivot level of 9.667, with resistance at 10.588 and 11.157, and support at 8.747 and 8.178. Overall, the chart is neutral-to-cautious rather than a clean buy setup.
["Immunic is advancing vidofludimus calcium in Phase 3 relapsing multiple sclerosis studies, which is the main long-term catalyst.", "Investor conference participation on 2026-04-30 may help keep attention on pipeline progress.", "Appointment of Michael Panzara as Chief Medical Officer on 2026-04-28 strengthens clinical leadership and development strategy.", "Analyst sentiment is mostly positive overall, with multiple Buy ratings and recent target support.", "Options open interest is heavily skewed toward calls, suggesting bullish positioning by traders."]
["The latest quarter shows continued losses, with net income at -19.3 million and EPS at -0.10.", "Revenue remains 0, so there is no commercial growth yet.", "MACD remains below zero and the trend is not yet confirmed bullish.", "A recent downgrade from D. Boral Capital to Hold reflects concern over reverse stock split and capital structure issues.", "No AI Stock Picker or SwingMax signal is present today.", "Hedge funds and insiders show no meaningful buying trend."]
In 2025/Q4, Immunic reported revenue of 0, unchanged year over year, so there is no operating revenue growth to highlight. Net income was -19.3 million, worsening 23.34% YoY, and EPS was -0.10, down 60% YoY. Gross margin was 0 because the company is still pre-commercial. For a beginner long-term investor, this means the story is still entirely dependent on future clinical success rather than current earnings strength.
Analyst sentiment is generally constructive but mixed on timing. H.C. Wainwright raised its price target to $22 from $5 and kept a Buy rating, mainly due to the reverse stock split adjustment. Stifel initiated Buy with a $2.50 target, citing Phase 3 potential and differentiated safety. Guggenheim also initiated Buy with a $7 target, calling for substantial upside if the Phase 3 data confirm the drug's profile. Offsetting this, D. Boral Capital downgraded the stock to Hold due to capital structure concerns and reverse split pressure. Wall Street's pros see meaningful pipeline upside, while the cons focus on dilution/capital structure and the lack of commercial revenue.
